Trial Profile
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2021.
- 03 Aug 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
- 03 Aug 2020 Status changed from recruiting to active, no longer recruiting.